Indazole-based synthetic cannabinoid AMB-FUBINACA, also known as FUB-AMB and MMB-FUBINACA, is a powerful cannabinoid agonist. It has Ki values of 10.04 nM at CB1 and 0.786 nM at CB2 and EC50 values of 0.5433 nM at CB1 and 0.1278 nM at CB2. It has been sold online as a designer drug. It was first made by Pfizer, which filed a patent for the compound in 2009. The compound was never tested on humans. There were a lot of drug seizures made by the DEA in 2017 and the first half of 2018. The most common synthetic cannabinoid was AMB-FUBINACA.

It is an indazole-based synthetic cannabinoid called AMB-FUBINACA, and it is a powerful agonist for the cannabinoid receptors. It has Ki values of 10.04 nM at CB1 and 0.786 nM at CB2, and EC50 values of 0.5433 nM at CB1 and 0.1278 nM at CB2. It has been sold online as a designer drug.